Adeno-associated viruses (AAV) are quickly emerging as the benchmark by which all other gene therapy delivery paradigms measure themselves. This tiny ssDNA virus is being utilized in an array of clinical trials to treat disorders such as Hemophilia, cystic fibrosis, and Parkinson’s disease. Still, its use in delivering potential pandemic ending vaccine material has vaulted its awareness to new heights. In this new GEN eBook we will explore various aspects of AAV bioproduction—looking at the challenges that many investigators face, and some of the novel solutions others have employed when ramping up viral production. Additionally, you can learn how new technology like artificial intelligence (AI) is allowing researchers to use AAV in exciting new ways and see how focused regulators are on safety measures during AAV production and use.